NCT01569633

Brief Summary

Objective of this study are: 1\) To determine if medication help extreme preterm infants to tolerate feeding better by reaching full feeding earlier.2) Out of two medication; which one is better for efficacy 1) Erythromycin 2) Metoclopramide. Infants who meet inclusion criteria would be entered to study after parental consent. Infant would be blinded to care givers. Infants will be randomized to receive one of three medication for 7-14 days. If infants fail on one medication they will be allowed to crossover to other medication. Infant would be allowed to treat like other infants. Blindness can be broken if deem necessary by attending neonatologist.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Oct 2011

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2011

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

March 30, 2012

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 3, 2012

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2014

Completed
1.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
Last Updated

November 21, 2022

Status Verified

November 1, 2022

Enrollment Period

2.3 years

First QC Date

March 30, 2012

Last Update Submit

November 17, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Comparison of Prokinetics and PLACEBO IN EARLY ENTERAL NUTRITION OF EXTREME PRETERM INFANTS; DOUBLE BLIND CROSS OVER TRIAL

    Time to reach full enteral feeding in both infants. Which of the two medication help better in reaching full enteral feeding.

    24 MONTHS

Secondary Outcomes (1)

  • Comaparison of Prokintics and Placebo in Early Enteral Nutrition of Extreme Preterm Infants; Double blind cross over trial.

    24 months

Study Arms (3)

Placebo

PLACEBO COMPARATOR

This group of infant will not receive any medication but sugar water or placebo

Drug: placebo

Metclopramide

ACTIVE COMPARATOR

This group of infants will receive Metoclopramide at 0.1mg/kg q8 hrs.

Drug: Metclopramide

Erythromycin

ACTIVE COMPARATOR

mediaction used to treat feeding disorder

Drug: Erythromycin

Interventions

Dose of metoclopramide is 0.1miligram per kilogram every eight hours for 7-14 days.

Also known as: reglan
Metclopramide

Dose of erythromycin is 1 miligram per kilogram every eight hours

Erythromycin

The dose of sugar water is 1 ml per 8 hours.

Placebo

Eligibility Criteria

AgeUp to 14 Days
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Weight below 1250 grams
  • Age less than 14 days
  • Feeding intolerance; If feeding residual more than 30% on q3 hr feeding; 5 times out of 8 times, feeding residual more than 20% on q4 hr feeding 4 feeding out of 6 feeding or failure to advance feeding of more than 20ml/kg in 72 hrs.

You may not qualify if:

  • GI malformation or perforation
  • Genetic disorder

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

East Tennessee State University

Johnson City, Tennessee, 37604, United States

Location

MeSH Terms

Conditions

Feeding and Eating DisordersNutrition DisordersPremature Birth

Interventions

MetoclopramideErythromycin

Condition Hierarchy (Ancestors)

Signs and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and SymptomsMental DisordersNutritional and Metabolic DiseasesObstetric Labor, PrematureObstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Intervention Hierarchy (Ancestors)

BenzamidesAmidesOrganic Chemicalspara-AminobenzoatesAminobenzoatesBenzoatesAcids, CarbocyclicCarboxylic AcidsChlorobenzoatesHydroxybenzoate EthersHydroxybenzoatesHydroxy AcidsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsPhenyl EthersPhenolsMacrolidesPolyketidesLactones

Study Officials

  • Darshan S Shah, MD

    East Tennessee State University

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Asst. Professor of Pediatrics

Study Record Dates

First Submitted

March 30, 2012

First Posted

April 3, 2012

Study Start

October 1, 2011

Primary Completion

February 1, 2014

Study Completion

December 1, 2015

Last Updated

November 21, 2022

Record last verified: 2022-11

Locations